Journal article
Growth impairment in Japanese children with inflammatory bowel disease: A multicenter prospective cohort study
Journal of pediatric gastroenterology and nutrition, Vol.81(5), pp.1216-1226
11/2025
DOI: 10.1002/jpn3.70202
PMID: 40874638
Abstract
Objectives
To investigate the prevalence and characteristics of growth impairment (GI) in children with inflammatory bowel disease (IBD).
Methods
In this prospective observational study, 402 children with ulcerative colitis (UC, n = 257) and Crohn's disease (CD, n = 145) were enrolled from the Japanese Pediatric IBD Registry (2012–2020). GI was defined by Paris classification criteria. Longitudinal outcomes were assessed in children with ≥2 years of follow-up (n = 307).
Results
At diagnosis, the GI prevalence was comparable between children with UC and CD (6.2% vs. 8.3%, p = 0.54). However, children with UC diagnosed at 0–4 years demonstrated significantly higher GI rates (35.3%) than older children (p < 0.001). All children with CD experiencing GI had small intestinal lesions. Among those with GI at diagnosis, fewer children with UC (9%) recovered growth at a 2-year follow-up than those with CD (50%). Among children with normal growth at baseline, new-onset GI occurred in 23% of UC and 16% of CD cases. Of these, 31% recovered within 2 years, while persistent GI was observed in 16% of UC and 11% of CD cases. Prolonged corticosteroid use at 1 year was more frequent in UC (31% vs. 19%, p = 0.02) and was significantly associated with persistent GI.
Conclusions
Distinct growth patterns exist in Japanese children with IBD. Children with UC diagnosed at 0–4 years are particularly vulnerable and may benefit from early, steroid-sparing treatment. The association between small intestinal lesions and GI in CD emphasizes the importance of small bowel evaluation. Age-specific, patient-centered growth monitoring is crucial to optimize long-term outcomes.
Details
- Title: Subtitle
- Growth impairment in Japanese children with inflammatory bowel disease: A multicenter prospective cohort study
- Creators
- Hirotaka Shimizu - National Center For Child Health and DevelopmentRyusuke Nambu - Saitama Children's Medical CenterNao Tachibana - Tokyo Metropolitan Children's Medical CenterReiko Kunisaki - Yokohama City University Medical CenterTakahiro Kudo - Juntendo UniversitySawako Kato - Shinshu UniversityTatsuki Mizuochi - Kurume UniversityHideki Kumagai - Jichi Medical UniversityMikihiro Inoue - Fujita Health UniversityNaomi Iwata - Aichi Medical UniversityTakeshi Saito - Chiba HospitalTakashi Ishige - Gunma UniversityToshifumi Yodoshi - Okinawa Prefectural Chubu HospitalAtsuko Noguchi - Akita UniversityShigeo Nishimata - Tokyo Medical UniversityTakahiro Mochizuki - Osaka Police HospitalShin ichiro Hagiwara - Osaka Women's and Children's HospitalMika Sasaki - Iwate Medical UniversityHitoshi Tajiri - Osaka Prefectural Medical CenterFumihiko Kakuta - Miyagi Children's HospitalEitaro Hiejima - Kyoto University HospitalItaru Iwama - Saitama Children's Medical CenterYuri Hirano - National Center For Child Health and DevelopmentToshiaki Shimizu - Juntendo UniversityKatsuhiro Arai - National Center For Child Health and Development
- Resource Type
- Journal article
- Publication Details
- Journal of pediatric gastroenterology and nutrition, Vol.81(5), pp.1216-1226
- DOI
- 10.1002/jpn3.70202
- PMID
- 40874638
- NLM abbreviation
- J Pediatr Gastroenterol Nutr
- ISSN
- 0277-2116
- eISSN
- 1536-4801
- Number of pages
- 11
- Grant note
- Sandoz K.K. EA Pharma Co., Ltd. Kyorin Pharmaceutical Co., Ltd. Mitsubishi Tanabe Pharma Corporation Kissei Pharmaceutical Co. Mochida Pharmaceutical Co. Ltd. JCR Pharma Alfresa Pharma Corporation. Nobelpharma Co., Ltd. Sekisui Medical Co., Ltd.
- Language
- English
- Date published
- 11/2025
- Academic Unit
- Stead Family Department of Pediatrics; Gastroenterology, Hepatology, Pancreatology, and Nutrition
- Record Identifier
- 9985214170502771
Metrics
3 Record Views